Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet

NCT00312026 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00312026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00312026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 30, 2006
Completion date
November 28, 2006
Enrollment
75
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis